COMMUNIQUÉS West-GlobeNewswire

Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
12/02/2024
FDA grants orphan drug designation to Ruxoprubart (NM8074) for the treatment of PNH. Ruxoprubart is an Anti-Bb antibody that selectively blocks the alternative pathway while maintaining the intactness of the classical [...]
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
12/02/2024
FREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company [...]
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
12/02/2024
Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor’s BVA-100 [...]
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
12/02/2024
TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated [...]
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
12/02/2024
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year [...]
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
12/02/2024
BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection testing at the Point-of-Care, announced a national distribution [...]
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
12/02/2024
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of [...]
Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego
12/02/2024
NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences. At BIO-Neuroscience, held in [...]
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
12/02/2024
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track [...]
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
12/02/2024
Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015 MDG1015 is a first-in-class, third generation TCR-T therapy targeting [...]
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
12/02/2024
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL ◊ AGILI-C ◊ Cartilage Repair Implant alongside the REGENETEN ◊ Bioinductive [...]
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
12/02/2024
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which NDA preparation is ongoing Investigator-Initiated OASIS Trial at UNC is a Phase 2 180-patient, [...]
Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
12/02/2024
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral [...]
Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
12/02/2024
Monrovia, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") – today [...]
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
12/02/2024
Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara’s Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE [...]
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
12/02/2024
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular [...]
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
12/02/2024
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO 2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all [...]
IBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per Share
12/02/2024
MONTREAL, Feb. 12, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 [...]
TECHNOLOGIES IBEX SIGNE UNE ENTENTE DÉFINITIVE VISANT LA VENTE DE LA SOCIÉTÉ POUR UNE CONTREPARTIE AU COMPTANT DE 1,45 $ PAR ACTION
12/02/2024
MONTRÉAL, 12 févr. 2024 (GLOBE NEWSWIRE) -- Technologies IBEX inc. (« IBEX » ou la « Société ») (Bourse de croissance TSX : IBT) est heureuse d’annoncer qu’elle a conclu une entente d’acquisition contraignante datée du [...]

Pages